The bactericidal/ permeability-increasing protein (BPI) ofneutrophils and BPI fragments neutralize the effects of isolated Gram-negative bacterial lipopolysaccharides both in vitro and in vivo. Since endotoxin most commonly enters the host as constituents of invading Gram-negative bacteria, we raised the question: Can BPI and its bioactive fragments also protect against whole bacteria? To determine whether the bactericidal and endotoxin-neutralizing activities of BPI / fragments are expressed when Gram-negative bacteria are introduced to the complex environment of whole blood we examined the effects of added BPI and proteolytically prepared and recombinant NH2-terminal fragments on: (a) the fate of serum-resistant encapsulated Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa that survive the antibacterial actions of whole blood and (b) the ability of these bacteria to trigger cytokine release. Added BPI in nanomolar concentrations killed each ofthree encapsulated strains ofE. coli and in closely parallel fashion inhibited tumor necrosis factor (TNF) release. Holo-BPI and its NH2-terminal fragment were equipotent toward a rough LPS chemotype Kl-encapsulated strain, but the fragment was substantially more potent than holo-BPI toward two encapsulated smooth LPS chemotype strains. TNF release induced by K. pneumoniae and P. aeruginosa was also inhibited by both holo-BPI and fragment but, at the protein concentrations tested, P. aeruginosa was killed only by the fragment and K. pneumoniae was not killed by either protein. The bactericidal action of BPI/fragment toward E. coli is inhibited by C7-depleted serum, but accelerated by normal serum, indicating that BPI, acting in synergy with late complement components, enhances extracellular killing of serum-resistant bacteria. Thus, BPI and an even more potent NH2-terminal fragment may protect against Gram-negative bacteria in the host by blocking bacterial proliferation as well as endotoxin-mediated
Introduction
The continued high mortality and morbidity attributable to Gram-negative bacteremia and endotoxemia have prompted an intense search for therapeutic agents capable of counteracting the potentially devastating effects of circulating bacterial LPS. Recently it has been shown that administration to septic patients of monoclonal antibodies directed against lipid A, the toxic portion of the LPS molecule, may reduce mortality ( 1, 2) . Since the systemic toxicity of endotoxin is thought to be mediated at least in part by excessive production of cytokines, such as tumor necrosis factor (TNF)a, I and various interleukins (1) (2) (3) (4) (5) (6) (7) (8) (9) , protection by antibodies directed at these host mediators or by antagonists of their receptors is now also being investigated.
The bactericidal/permeability-increasing protein (BPI), a product of PMN of man and animals that is stored in the azurophilic granules, is cytotoxic for Gram-negative bacteria only (10) (11) (12) . This remarkable target-cell specificity of BPI is attributable to its strong attraction to the LPS in the outer membrane of the Gram-negative bacterial envelope (13) (14) (15) . This feature of BPI has led to the recognition that BPI is a member of a family of LPS-binding proteins (16) and is capable, when added extracellularly, of inhibiting effects of purified LPS in several in vitro settings (17) (18) (19) as well as in animal experiments (20). It has been suggested that under these conditions the LPS-neutralizing activity of BPI, directed at cell-free LPS, represents its main biological role, outweighing its importance as an antibacterial agent (8, 19) . However, the most common presentation of LPS to the host is as an envelope component of invading bacteria. Therefore, the ability of added BPI and its bioactive fragments to attach to LPS in the bacterial envelope and to cause bacterial damage may be an important determinant of its protective action in vivo.
We now show that the addition of nanomolar concentrations ofthe 55-kD holo-BPI or ofthe -23-25-kD NH2-termi-nal bioactive portion of the molecule to whole blood inoculated with live encapsulated Gram-negative bacteria can result in both killing ofbacteria that survive the cellular and extracellular antibacterial systems present in whole blood and inhibition of the release of TNF prompted by the bacteria.
Methods
Bacteria. Bacteria used in this study included Escherichia coli J5, a rough UDP-galactose-4-epimeraseless mutant of the smooth strain 01111:B4 (13), a K 1-encapsulated rough LPS chemotype strain of E. coli ("K1 /r") kindly provided by Dr (23) .
BPI and BPI NH2-terminalfragments. Human BPI (nBPI-55) was purified from crude extracts of PMN-rich populations using E. coli as an affinity matrix, as previously described ( 15) . An -25-kD NH2-terminal fragment of human BPI (nBPI-25) was isolated after limited proteolysis ofpurified human BPI as described before (24) . A recombinant NH2-terminal fragment of BPI (rBPI-23) was expressed in Chinese hamster ovary cells after transfection with an expression vector containing human BPI cDNA (25) modified to contain a stop codon after amino acid 199. Details of the design of the expression vector containing BPI cDNA and the procedure for purification ofthe recombinant protein will be presented in a separate manuscript (GazzanoSantoro, H., J. B. Parent, L. Grinna, A. Horwitz, T. Parsons, G. Theotan, P. Elsbach, J. Weiss, and P. J. Canlan, manuscript in preparation). The identity and purity of the recovered protein were confirmed by NH2-terminal amino acid sequencing and SDS-PAGE. Protein mass was estimated by a protein assay kit (Bio-Rad Laboratories, Richmond, CA) and by absorbance at 280 nm, with BSA as the standard. Protein estimates were confirmed by Coomassie blue staining after SDS-PAGE. All protein samples were dialyzed against and stored in 20 mM sodium acetate/acetic acid buffer, pH 4.0.
Blood. Blood was collected from healthy human volunteers after informed consent into tubes containing citrate or heparin as an anticoagulant (Becton Dickinson, Mountain View, CA). Unless indicated otherwise, blood samples contained 275 ,u ofcitrated blood, 5 tsl ofBPI (fragment) in acetate buffer (or buffer alone) and 20 ,l of bacteria or LPS diluted in sterile physiological saline or HBSS -(or diluent alone), respectively. Bacteria or LPS was added last. Samples were incubated at 37°C for up to 5 h before measurement of bacterial viability and TNF in the extracellular medium.
Sera. Venous blood was collected from healthy volunteers. The serum was collected after clot formation, centrifuged at 10,000 g for 20 min to remove any debris, and stored at -70°C. C7-depleted human serum and purified human C7 were purchased from Quidel (San Diego, CA). The quality ofthese products was pretested by confirming the loss in C7-depleted serum of bactericidal activity toward a serumsensitive strain ofE. coli (J5) and the restoration ofbactericidal activity to the level ofnormal serum by supplementing the depleted serum with purified C7 (final concentration of 60 ,g/ml).
Measurement ofbacterial viability. After the indicated incubations at 37°C, aliquots were taken and serially diluted in sterile physiological saline. A 25-Al aliquot of the diluted sample was transferred to 5 ml of 1.3% (wt/vol) molten (48°C) Bactoagar (Difco Laboratories Inc., Detroit, MI) containing either 0.8% (wt/vol) nutrient broth and 0.5% (wt/vol) NaCl (for plating of E. coli) or 3% (wt/vol) trypticase soy broth (for plating of S. aureus) and poured into a petri dish. Where indicated, the molten agar was supplemented with 1 mg/ml BSA (United States Biochemical Corp., Cleveland, OH). The agar was allowed to solidify at room temperature, and bacterial viability was measured as the number of colonies formed after incubation at 37°C for 18-24 h. Brief sonication of blood samples before serial dilutions, as previously described (26), did not increase the number of bacterial colonies formed.
Measurement ofextracellular accumulation ofTNF in whole blood. After incubation of blood samples for 5 h at 37°C, the samples were diluted four times with RPMI and spun at 500 g for 5 min to collect the extracellular medium. TNF in the recovered medium was measured by ELISA using the Biokine TNF test kit (T Cell Sciences, Inc., Cambridge, MA).
Results
Selection ofa suitable experimental model. To provide an experimental setting in which both the bactericidal and the antiendotoxin activities of BPI and its NH2-terminal fragment could be tested in whole blood, we initially examined the ability of added live E. coli to survive in blood and trigger extracellular accumulation of TNF. Among the test organisms selected first was a K1-encapsulated E. coli strain, containing short chain (rough chemotype) LPS ("K1 /r"). This highly BPI-sensitive organism (21 ) because ofthe presence of (K1 ) capsule is likely to be resistant to the cellular and extracellular antibacterial systems in blood (21, 27, 28) and representative of strains that are prominent in clinical infections (29) (30) (31) . We have shown before that ( K 1 ) capsule does not increase bacterial resistance to BPI (21) . At low doses of bacteria added to whole blood, few bacteria survived during 5 h incubations ( Fig. 1 A) . However, with larger inocula, the surviving fraction increased and outgrowth of surviving bacteria was observed. In contrast, a rough strain of E. coli (J5; Fig. 1 A) , as well as two clinical blood isolates of E. coli (data not shown), were rapidly and virtually completely killed in blood at all bacterial doses tested (up to I07/ ml). Despite their differences in survival, both E. coli J5 and the K 1-encapsulated strain were potent inducers of TNF release in blood ( Fig. 1 B) . The TNF-inducing activity of the bacteria was dose-dependent and was even more pronounced than that of purified LPS added in amounts corresponding to the LPS content of the whole bacteria ( Fig. 1 B) .
Added BPI inhibits survival ofE. coli and accumulation of extracellular TNF in whole blood. Based on the preceding experiments, we chose the K 1-encapsulated strain (E. coli Kl /r) to test the antibacterial activities of BPI/fragments added to whole blood. Fig. 2 shows that holo-BPI (nBPI-55) potently inhibited both bacterial survival (Fig. 2 , A-C) and release of TNF (Fig. 2 D) in whole blood. Both effects of BPI were dose dependent and apparent over a broad range of bacterial concentrations and were observed in blood anticoagulated either with citrate or with heparin ( 10 U/ml). At ,gg/ml; -40 nM) tested, BPI reduced bacterial survival by > 100-fold and bacterial TNF-inducing activity by 100-fold (i.e., caused a 100-fold increase in the bacterial dose necessary for induction of TNF).
Effects ofNH2-terminalfragment(s) ofBPI. An -25-kD NH2-terminal fragment of BPI, generated during limited proteolysis, exhibits all the known biological activities of holo-BPI ( 18, 24) . Fig. 3 shows that this fragment and a corresponding recombinant product are as potent as holo-BPI in reducing survival of E. coli Kl /r (Fig. 3 A) and bacterial induction of TNF accumulation (Fig. 3 , B-E) in whole blood. The activities exhibited by the recombinant BPI fragment confirm our prediction that all ofthe molecular determinants for the antibacterial activities of BPI toward Gram-negative bacteria reside within the NH2-terminal region encompassed by residues 1-199 (18 (32) have shown that serum albumin (2 0.5 mg/ml) specifically inhibits the progression of BPI action from sublethal to lethal injury and that during prolonged incubation (2 2 h) in albumin-supplemented media BPI-treated bacteria that have suffered only sublethal damage regain their normal ability to grow (e.g., ability to form colonies in nutrient agar). In whole blood the albumin effect is not apparent. Fig. 2 , A-C, shows that the growth-inhibitory effect of added BPI on E. coli Kl /r is sustained during long incubations (up to 5 h) in whole blood (and not reversed when samples from blood are plated on nutrient agar supplemented with albumin) therefore indicating that in whole blood added BPI causes irreversible inhibition of bacterial growth (i.e., bacterial killing) despite the presence ofhigh concentrations ofalbumin.
To determine whether other elements in the extracellular environment of blood can override the inhibitory effect ofalbumin on BPI action, we compared the antibacterial action of BPI on E. coli Kl /r in buffered mixtures ofnutrient broth and physiological saline either without or with added purified albumin ( 12.5 mg/ml) or with whole serum containing the same concentration ofalbumin. In each medium, BPI promptly arrested colony formation in nutrient agar by > 98% of the bacteria (Fig. 4 B, broken lines) . However, as shown before (32), after 15 min incubation, most of the bacteria formed colonies when plated in nutrient agar supplemented with albumin (Fig. 4 B, solid lines) indicating that damage to these bacteria at this time was still sublethal and hence reversible during incubation in albumin-supplemented medium. After longer incubation in nutrient broth without added albumin, progressively fewer BPI-treated bacteria could form colonies in albumin-supplemented nutrient agar ( Fig. 4 B, open squares, solid line) demonstrating the slow progression of BPI action to the irreversible lethal stage (32) . This progression was blocked when albumin was included in the incubation medium (Fig. 4 B, open circles, solid line). In contrast, a nonlethal dose of serum (Fig. 4 A) overcame the albumin block and actually markedly accelerated the rate of killing of BPI-treated bacteria (Fig. 4 B, closed circles, solid line). Serum depleted of C7 acted like purified albumin and inhibited killing of BPI-treated bacteria (Fig. 4 B, open triangles, solid line). Purified C7 alone had no effect on BPI action but together with C7-depleted serum reproduced the effect ofnormal serum (Fig. 4 B, closed triangles, solid line) showing that the enhancement of bacterial killing by normal serum plus BPI is dependent on late components of the complement system acting synergistically with BPI.
Effects ofBPI/fragment on survival and TNF-inducing activity ofother bacteria in whole blood. Because the presence of long polysaccharide chains (0-antigen) in LPS reduces the affinity of BPI for the envelope of Gram-negative bacteria ( 13, 24), we also examined the antibacterial actions of BPI/fragment against two encapsulated strains of E. coli (07:Kl and 0lO:K5) containing long chain (smooth chemotype) LPS. At inocula of 105 or 106 bacteria/ml of either strain, bacterial viability was not reduced after 1 h in blood alone (Fig. 5) . Addition of either holo-BPI or its NH2-terminal fragment produced a dose-dependent inhibition ofbacterial viability and, in closely parallel fashion, inhibition ofTNF release. However, in contrast to the equal potency of holo-BPI and the fragment toward E. coli Kl /r, the fragment (at fivefold higher doses than required for killing of E. coli Kl /r) was from 5-10-fold more potent than the holo-protein toward both E. coli 07:Kl and E. coli 0lO:K5. The fragment was also substantially more potent than holo-BPI toward one strain ofP. aeruginosa. However, in contrast to the parallel bactericidal and TNF-inhibitory effects of both proteins on E. coli, these effects were not similar in the case of P. aeruginosa and a mucoid strain of K. pneumoniae.
Both holo-BPI and the fragment potently inhibited TNF release induced by these bacteria, but holo-BPI had no significant effect on survival of either organism (at the doses tested) and the fragment killed only the Pseudomonas strain at a 5-10-fold higher concentration than needed for its TNF-inhibitory effect (Fig. 5) . Thus, the induction of TNF by various Gram-negative bacteria was inhibited by the two proteins whether or not the bacteria were killed.
In contrast to the effects of BPI/fragment on each of the Gram-negative bacteria tested neither BPI nor the fragment affected survival or extracellular TNF accumulation when the Gram-positive bacterium Staphylococcus aureus was introduced to whole blood (Fig. 5 ). and extracellular accumulation of TNF (C-E) were measured as described in Methods after incubation of Kl-encapsulated E. coli ( 103-106/ml) in blood supplemented with increasing concentrations of native holo-BPI (nBPI-55) or an NH2-terminal fragment of BPI obtained either by limited proteolysis (nBPI-25) or by expression of a truncated form of human BPI cDNA (rBPI-23). Bacterial colony-forming units (CFU) were measured after 1 h incubation of 106 E. coli/ml and are expressed as the percentage of CFU of bacteria incubated in blood alone (representing 75±15% of the CFU of the initial inoculum). The effect of added holo-BPI and BPI fragments on the ability ofthe bacteria to induce extracellular TNF accumulation ( TNF-inducing activity; B) was calculated by comparing the bacterial dose requirements for triggering TNF accumulation in the absence and presence of BPI (fragment) (C-E). For example, an increase in bacterial dose requirement of 2-, 10-, and 100-fold corresponds, respectively, to a reduction of bacterial TNF-inducing activity to 50, 10, and 1% of control (untreated bacteria). For a given amount of BPI/fragment added, a similar shift in the dose curve was observed at each bacterial dose tested. Therefore, each dose point was used to calculate the effects of added BPI (B). This effect is expressed as percent TNF-inducing activity of the added bacteria, using a bacterial standard curve as shown in Fig. 2 D. Each value shown represents the mean±SEM of at least four independent determinations (A and B) or of at least two determinations (C-E).
Discussion
BPI is located in the primary granules of PMN and is the most potent antibacterial agent yet identified in the antimicrobial arsenal of this phagocyte, directed specifically at a broad range of Gram-negative bacterial species (10, 33) . We have demonstrated before that the remarkable target cell specificity of BPI reflects the strong attraction ofthis protein for the lipopolysaccharides that are the dominant surface molecules of the outer membrane of the Gram-negative bacterial envelope (13) (14) (15) 21 ). It is to this interaction that we attribute the prompt growth inhibitory effects and surface alterations that isolated BPI exhibits upon binding to E. coli and other Gram-negative bacteria (10, 32) . The fate of bacteria ingested by PMN in vitro, both under aerobic and anaerobic conditions, closely mimics that of bacteria exposed to purified BPI, lending credence to the conclusion that BPI also is primarily responsible for growth arrest within the phagocyte ( 10, 26, 34) .
In light ofthe strong evidence implicating the essential role of the recognition by BPI of LPS in the bacterial envelope in the selective action of BPI on Gram-negative bacteria, it is not surprising that recent studies have revealed that BPI is a member of a family of LPS-binding proteins ( 16) . One of these, LPS-binding protein or LBP, has been shown to mediate and amplify host responses to LPS (35) (36) (37) Time (min) Figure 4 . Synergistic bactericidal action of BPI and complement against serum-resistant K 1-encapsulated E. coli. E. coli (2 x 106/ml) were incubated in the absence (A) and presence (B) of holo-BPI (2 ,g/ml) in buffered (20 mM sodium phosphate, pH 7.4) nutrient broth supplemented with physiological (0.9%) saline or saline containing purified albumin (12.5 mg/ml), 25% normal serum (vol/vol), 25% C7-depleted serum, or 25% C7-depleted serum plus purified C7 (50 Ag/ml). After incubation at 37°C for the indicated times, aliquots were taken to measure bacterial viability in unsupplemented nutrient agar (broken lines) and in nutrient agar supplemented with 1 mg of albumin/ml (solid lines).
In the absence of BPI, there was no difference in the number of CFU apparent in nutrient agar±albumin. The CFU in a given sample are expressed as the percentage of the CFU of the added bacteria at time zero. The data shown represent the mean±SEM of at least three independent experiments.
Because the systemic entry of LPS into the host is usually secondary to invasion by Gram-negative organisms we addressed the questions: Can BPI and its bioactive fragments perform their antibacterial functions in the complex environment of whole blood and prevent in this setting the effects of the bacteria on cellular responses typical of Gram-negative bacteremia?
Mannion et al. (32) have shown before that when albumin is added as an isolated protein to an artificial incubation medium, the initial (almost immediate) actions of BPI, including binding, outer membrane alterations, and (reversible) growth inhibition are unaffected, but the later stage(s) of BPI action, involving cytoplasmic membrane damage and concomitant irreversible growth inhibition (cell death), is (are) blocked. These observations have prompted some to speculate that any extracellular function of BPI in vivo would be limited to neutralization of LPS (8, 19) . However, we have now shown that added (extracellular) BPI and its bioactive fragments not only inhibit the accumulation of TNF in whole blood in response to the introduction of live E. coli, but also increase killing of E. coli in blood. These effects are evident at the same nanomolar concentrations that are effective in simple laboratory media, indicating that in the far more complex environment of whole blood neither cellular nor extracellular elements prevent BPI and its NH2-terminal fragments from finding their natural targets. In fact, when encapsulated E. coli is exposed to BPI in the presence ofnonlethal concentrations ofserum, bacterial killing is markedly accelerated reflecting synergistic effects of BPI/ fragment and late components of the complement system on E. coli (see Fig. 4 ). We have previously observed similar potentiation by late components ofcomplement on intracellular killing ofE. coli by PMN (26) , suggesting that the functions ofBPI and the complement system are joined to serve a major role in host defenses against Gram-negative bacteria. Because BPI causes prompt bacteriostasis and discrete surface alterations, even in the presence ofalbumin as sole additive (Fig. 3 B) (32) , it is possible that BPI renders the serum-resistant Kl-encapsulated E. coli more susceptible to complement in a manner similar to what has been reported for a nonbactericidal derivative of polymyxin B (38, 39) . However, the late effects of BPI (32) and the bactericidal action of the membrane attack complex (40-42) cannot be distinguished so that the role of each, and possibly of additional antimicrobial blood elements, in the sequence of events in whole blood leading to bacterial death cannot yet be determined. Whatever the nature of the synergistic action of BPI and late complement components, it is the addition of BPI or the NH2-terminal fragment that results in killing ofsurviving E. coli. These findings raise the possibility that BPI and its NH2-terminal fragment, administered to whole animals and man, may serve a dual beneficial role, i.e., by enhancing the destruction of extracellular Gram-negative bacteria and by inhibiting their induction of potentially harmful cytokine (TNF) release.
The spectrum of bactericidal activity of BPI against the organisms tested in blood mirrored the action of BPI in simpler (serum-free) media (data not shown), suggesting that the inherent ability of BPI to act on a given organism primarily determines that organism's fate in blood when BPI is added. Because encapsulated bacteria (E. coli) are as sensitive to BPI as nonencapsulated strains ( 10, 21 ) , bacteria that are highly resistant to both the cellular and extracellular elements of normal blood can still be effectively eliminated upon addition ofnanomolar concentrations of BPI. The presence oflong polysaccharide chains in outer membrane LPS, however, does increase bacterial resistance to holo-BPI ( 10, 13, 21, 43) but much less so to the NH2-terminal fragment (24; Fig. 5 holo-BPI and BPI fragments on bacterial TNF-inducing activity was calculated by comparing TNF accumulation triggered by increasing concentrations of bacteria in the absence and presence of BPI (fragment) as described in the legend to Fig. 3 . Each value shown represents the mean of from two to six independent determinations. of Gram-negative bacteria, including P. aeruginosa and K. pneumoniae, are sensitive to BPI ( 10, 44, 45 ; unpublished observations). The unexpected resistance of the strains of these organisms used in this study most likely reflects our selection of phenotypes that survive in normal blood. Both P. aeruginosa and K. pneumoniae are opportunistic pathogens that often cause disease when host defense is compromised.
The potency of all the Gram-negative bacteria tested as inducers of TNF accumulation in whole blood is remarkable. Addition of as little as 1 bacterium per ,l ofblood (containing ca. 7000 leukocytes) suffices to trigger the release of detectable amounts of extracellular TNF (Fig. 1 B) . The TNF-inducing activity of these whole Gram-negative bacteria is at least as great as of amounts of isolated LPS that equal the total bacterial LPS content (Fig. 1 B) . Thus, if LPS released by the bacteria is to account for the TNF-inducing activity of E. coli (46, 47) , such release must be nearly quantitative. This seems unlikely in the case of organisms that remain viable in blood. Alternatively, the TNF-inducing potency of LPS released by the bacteria is far greater than of equivalent amounts of extracted and purified LPS. It is also possible that LPS within the bacterial envelope, perhaps in combination with other envelope constituents, further contributes to cytokine production and release. Whatever the nature of the inciting bacterial agent(s), we show that holo-BPI and the NH2-terminal fragment are potent inhibitors of TNF release induced not only by isolated LPS (17) (18) (19) but also by added bacteria, whether dead or alive. Presentation to blood of equal numbers of bacteria that either survive or are promptly killed in blood alone (Fig.  B) triggers comparable TNF responses. Thus, the detection in blood cultures from septic patients of viable organisms is not an accurate index of the bacterial challenge to host responses. In the uncompromised host with Gram-negative bacteremia many species of Gram-negative bacteria are effectively killed by the intrinsic antimicrobial systems, but without protection against the actions of the cytokines released in response to circulating dead bacteria or their products. However, sepsis is particularly prevalent among patients with impaired antibacterial defenses in whom the bacteremia includes viable and proliferating organisms.
Earlier work in this laboratory has shown that BPI is less readily released from the PMN upon stimulation with degranulating agents than are other granule proteins (48) , consistent with some of BPI's structural properties (25) and a primary intracellular (phagosomal) function. Indeed, BPI has been shown to coat ingested, but not extracellular, E. coli during incubation with PMN (49) . However, these observations do not exclude the possibility that under certain in vivo conditions BPI is released in biologically active form and concentrations. Thus far there is no evidence to support the claim that BPI is released in appreciable amounts by PMN under physiologic conditions. The fact that minute amounts of LPS added to whole blood ex vivo elicit cytokine production and release and that added BPI or BPI fragments in nanomolar concentrations inhibit this response implies that if BPI is present in the extracellular environment of normal blood its concentration does not exceed 10 nM (Fig. 3) .
The results of this study, in combination with very recent whole animal experiments, showing protection against administered LPS by recombinant holo-BPI (20), as well as by recombinant NH2-terminal fragment (unpublished observations) support the possibility that BPI and particularly the bioactive NH2-terminal portion ofthe molecule are important additions to a group of potential therapeutic proteins and agents that may serve in the treatment of Gram-negative bacteremia and endotoxemia. BPI stands out among these agents in two ways: (a) as a natural component ofthe antimicrobial systems ofthe host, and (b) as the only agent so far identified with both bactericidal and endotoxin-neutralizing activities. This report further shows that the NH2-terminal recombinant fragment as an administered extracellular agent may possess greater antibacterial range and potencies than the holo-protein.
